Clinicians face challenges in the treatment of triple-negative breast cancer (TNBC) because TNBC cells do not express specific proteins, namely, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.